<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcmedgenet&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Medical Genetics - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcmedgenet/</link>
        <description>The latest research articles published by BMC Medical Genetics</description>
        <dc:date>2009-12-04T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/127" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/126" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/125" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/124" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/123" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/122" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/121" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/120" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/119" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2350/10/118" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/127">
        <title>Power of multifactor dimensionality reduction and penalized
logistic regression for detecting gene-gene interaction in a
case-control study</title>
        <description>Background:
There is a growing awareness that interaction between multiple genes play an important role in the risk of common, complex multi-factorial diseases. Many common diseases are affected by certain genotype combinations (associated with some genes and their interactions). The identification and characterization of these susceptibility genes and gene-gene interaction have been limited by small sample size and large number of potential interactions between genes. Several methods have been proposed to detect gene-gene interaction in a case control study. The penalized logistic regression (PLR), a variant of logistic regression with L2 regularization, is a parametric approach to detect gene-gene interaction. On the other hand, the Multifactor Dimensionality Reduction (MDR) is a nonparametric and genetic model-free approach to detect genotype combinations associated with disease risk.
Methods:
We compared the power of MDR and PLR for detecting two-way and three-way interactions in a case-control study through extensive simulations. We generated several interaction models with different magnitudes of interaction effect. For each model, we simulated 100 datasets, each with 200 cases and 200 controls and 20 SNPs. We considered a wide variety of models such as models with just main effects, models with only interaction effects or models with both main and interaction effects. We studied the effect of different allele frequencies on these methods. We also compared the performance of MDR and PLR to detect gene-gene interaction associated with acute rejection(AR) in kidney transplant patients.
Results:
As expected, none of these methods were consistently better for all data scenarios, but, generally MDR outperformed PLR for more complex models. The ROC analysis on the real dataset suggests that MDR outperforms PLR in detecting gene-gene interaction on the real dataset.
Conclusions:
As one might expect, the relative success of each method is context dependent. This study demonstrates the strengths and weaknesses of the methods to detect gene-gene interaction.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/127</link>
                <dc:creator>Hua He</dc:creator>
                <dc:creator>William Oetting</dc:creator>
                <dc:creator>Marcia Brott</dc:creator>
                <dc:creator>Saonli Basu</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:127</dc:source>
        <dc:date>2009-12-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-127</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>127</prism:startingPage>
        <prism:publicationDate>2009-12-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/126">
        <title>The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves&apos; disease, Hashimoto&apos;s thyroiditis and Addison&apos;s disease
</title>
        <description>Background:
Three genes have been confirmed as major joint susceptibility genes for endocrine autoimmune disease:human leukocyte antigen class II, cytotoxic T-lymphocyte antigen 4 and protein tyrosine phosphatase non-receptor type 22. Recent studies showed that a genetic variation within the interferon induced helicase domain 1 (IFIH1) locus (rs1990760 polymorphism) is an additional risk factor in type 1 diabetes and Graves&apos; disease (GD). Methods:The aim of the present study was to investigate the role of the rs1990760 polymorphism within the IFIH1 gene in German patients with GD (n=258), Hashimoto&apos;s thyroiditis (HT,n=106), Addison&apos;s disease (AD,n=195) and healthy controls (HC,n=227) as well as in 55 GD families (165 individuals, German) and 100 HT families (300 individuals, Italian). Furthermore, the interaction between rs1990760 polymorphism with human leukocyte antigen (HLA) risk haplotype DQ2(DQA*0501-DQB*0201), the risk haplotypes DQ2/DQ8 (DQA*0301-DQB*0302) and the status of thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb) and TSH receptor antibody (TRAb) in patients and families were analysed. Results:No significant differences were found between the allele and genotype frequencies for rs1990760 IFIH1 polymorphism in patients with GD, HT, AD and HC. Also no differences were observed when stratifying the IFIH1 rs1990760 polymorphism for gender, presence or absence of thyroid antibodies (GD:TRAb and HT:TPOAb/TgAb) and HLA risk haplotypes (DQ2:for GD and HT, DQ2/DQ8:for AD). Furthermore the transmission analysis in GD and HT families revealed no differences in alleles transmission for rs1990760 IFIH1 from parents with or without HLA risk haplotype DQ2 to the affected offspring. In contrast, by dividing the HT parents according to the presence or absence of thyroid Ab titers, mothers and fathers both positive for TPOAb/TgAb overtransmitted the allele A of IFIH1 rs1990760 to their HT affected offspring (61.8% vs 38.2%;p=0.05;corrected p [pc]=0.1). However, these associations did not remain statistically significant after correction of the p-values.
Conclusion:
In conclusion, our data suggest, no contribution from IFIH1 rs1990760 polymorphism to the pathogenesis of either Graves&apos; disease, Hashimoto&apos;s thyroiditis or Addison&apos;s disease in our study populations. However, in order to exclude a possible influence of the studied polymorphism in specified subgroups within patients with autoimmune thyroid disease, further investigations in larger populations are needed.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/126</link>
                <dc:creator>Marissa Penna-Martinez</dc:creator>
                <dc:creator>Elizabeth Ramos-Lopez</dc:creator>
                <dc:creator>Inka Robbers</dc:creator>
                <dc:creator>Heinrich Kahles</dc:creator>
                <dc:creator>Stefanie Hahner</dc:creator>
                <dc:creator>Holger Willenberg</dc:creator>
                <dc:creator>Nicole Reisch</dc:creator>
                <dc:creator>Christian Seidl</dc:creator>
                <dc:creator>Maria Segni</dc:creator>
                <dc:creator>Klaus Badenhoop	:</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:126</dc:source>
        <dc:date>2009-12-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-126</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>126</prism:startingPage>
        <prism:publicationDate>2009-12-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/125">
        <title>Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China</title>
        <description>Background:
Molecular epidemiological studies have shown that gene polymorphisms of vitamin D receptor (VDR) are associated with prostate cancer risks. However, previous results from many molecular studies remain inconsistent.
Methods:
Blood samples were collected from 122 prostate cancer patients and 130 age-matched control subjects in the Han population of Southern China. The differences of VDR gene polymorphism between cancer cases and controls were determined by PCR-RFLP, examiming FokI (exon 2), BsmI, Tru9I, ApaI (intron 9), and TaqI (exon 9). Association between the VDR gene polymorphism and prostate cancer risk were calculated in an unconditional logistic regression model. Linkage disequilibrium and haplotypes were analyzed with the SHEsis software.
Results:
Of five polymorphisms, BsmI was shown to associate with prostate cancer, while FokI, Tru9I, ApaI, and TaqI did not show any significant association. After adjustment for age, the BsmI &apos;B&apos; allele was associated with an almost 1/3-fold risk (OR=0.35, 95%CI: 0.15-0.80) of the occurrence of prostate cancer, a 1/5-fold risk (OR=0.20, 95%CI: 0.06-0.68) of poorly differentiated prostate cancer, and a 1/10-fold risk (OR=0.10, 95%CI: 0.01-0.78) of aggressive prostate cancer compared with the &apos;b&apos; allele, especially among older men (&gt;71 years ). In addition, haplotype analysis revealed that the &apos;F-b-U-A-T&apos; was more frequent found in cases than in controls (3.4% vs 0.0%, P=0.0035), while the frequency of haplotype &apos;F-B-U-a-T&apos; was 0.8% in cases, significantly lower than in controls (3.9%, P=0.019).
Conclusions:
Our experiments provide evidences that genetic polymorphisms in the VDR gene may be potential risk factors for prostate cancer in the Han population of southern China and the susceptibility to prostate cancer is associated with ethnicity and geographic location.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/125</link>
                <dc:creator>Yongheng Bai</dc:creator>
                <dc:creator>Yaping Yu</dc:creator>
                <dc:creator>Bin Yu</dc:creator>
                <dc:creator>Jianrong Ge</dc:creator>
                <dc:creator>Jingzhang Ji</dc:creator>
                <dc:creator>Hong Lu</dc:creator>
                <dc:creator>Jia Wei</dc:creator>
                <dc:creator>Zhiliang Weng</dc:creator>
                <dc:creator>Zhihua Tao</dc:creator>
                <dc:creator>Jianxin Lu</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:125</dc:source>
        <dc:date>2009-12-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-125</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>125</prism:startingPage>
        <prism:publicationDate>2009-12-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/124">
        <title>Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population</title>
        <description>Background:
Genetic influences on drug efficacy and tolerability are now widely known. Pharmacogenetics has thus become an expanding field with great potential for improving drug efficacy and reducing toxicity. Many pharmacologically-relevant polymorphisms do show variability among different populations. Knowledge of allelic frequency distribution within specified populations can be useful in explaining therapeutic failures, identifying potential risk groups for adverse drug reactions (ADRs) and optimising doses for therapeutic efficacy. We sought to determine the prevalence of clinically relevant Cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2C19 variants in Ghanaians. We compared the data with other ethnic groups and further investigated intra country differences within the Ghanaian population to determine its value to pharmacogenetics studies.
Methods:
RFLP assays were used to genotype CYP2C8 (*2, *3, *4) variant alleles in 204 unrelated Ghanaians. CYP2C9*2 and CYP2C19 (*2 and *3) variants were determined by single-tube tetra-primer assays while CYP2C9 (*3, *4, *5 and *11) variants were assessed by direct sequencing.
Results:
Allelic frequencies were obtained for CYP2C8*2 (17%), CYP2C8*3 (0%),  CYP2C8*4 (0%), CYP2C9*2 (0%), CYP2C9*3 (0%), CYP2C9*4 (0%), CYP2C9*5 (0%), CYP2C9*11 (2%), CYP2C19*2 (6%) and CYP2C19*3 (0%).
Conclusion:
Allele frequency distributions for CYP2C8, CYP2C9 and CYP2C19 among the Ghanaian population are comparable to other African ethnic groups but significantly different from Caucasian and Asian populations. Variant allele frequencies for CYP2C9 and CYP2C19 are reported for the first time among indigenous Ghanaian population.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/124</link>
                <dc:creator>William Kudzi</dc:creator>
                <dc:creator>Alexander Dodoo</dc:creator>
                <dc:creator>Jeremy Mills</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:124</dc:source>
        <dc:date>2009-12-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-124</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>124</prism:startingPage>
        <prism:publicationDate>2009-12-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/123">
        <title>Analyses of associations between three positionally cloned asthma candidate genes and asthma or asthma-related phenotypes in a Chinese population</title>
        <description>Background:
Six asthma candidate genes, ADAM33, NPSR1, PHF11, DPP10, HLA-G, and CYFIP2, located at different chromosome regions have been positionally cloned following the reported linkage studies. For ADAM33, NPSR1, and CYFIP2, the associations with asthma or asthma-related phenotypes have been studied in East Asian populations such as Chinese and Japanese. However, for PHF11, DPP10, and HLA-G, none of the association studies have been conducted in Asian populations. Therefore, the aim of the present study is to test the associations between these three positionally cloned genes and asthma or asthma-related phenotypes in a Chinese population.
Methods:
Two, five, and two single nucleotide polymorphisms (SNPs) in the identified top regions of PHF11, DPP10, and HLA-G, respectively, were genotyped in 1183 independent samples. The study samples were selected based on asthma affectation status and extreme values in at least one of the following three asthma-related phenotypes: total serum immunoglobulin E levels, bronchial responsiveness test, and skin prick test. Both single SNP and haplotype analyses were performed.
Results:
We found that DPP10 was significantly associated with bronchial hyperresponsiveness (BHR) and BHR asthma after the adjustment for multiple testing; while the associations of PHF11 with positive skin reactions to antigens and the associations of HLA-G with BHR asthma were only nominally significant.
Conclusions:
Our study is the first one to provide additional evidence that supports the roles of DPP10 in influencing asthma or BHR in a Chinese population.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/123</link>
                <dc:creator>Huanyu Zhou</dc:creator>
                <dc:creator>Xiumei Hong</dc:creator>
                <dc:creator>Shanqun Jiang</dc:creator>
                <dc:creator>Hongxing Dong</dc:creator>
                <dc:creator>Xiping Xu</dc:creator>
                <dc:creator>Xin Xu</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:123</dc:source>
        <dc:date>2009-12-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-123</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>123</prism:startingPage>
        <prism:publicationDate>2009-12-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/122">
        <title>Further analysis of previously implicated linkage regions for Alzheimer&apos;s disease in affected relative pairs</title>
        <description>Background:
Genome-wide linkage studies for Alzheimer&apos;s disease have implicated several chromosomal regions as potential loci for susceptibility genes.
Methods:
In the present study, we have combined a selection of affected relative pairs (ARPs) from the UK and the USA included in a previous linkage study by Myers et al. (Am J Med Genet, 2002), with ARPs from Sweden and Washington University. In this total sample collection of 397 ARPs, we have analyzed linkage to chromosomes 1, 9, 10, 12, 19 and 21, implicated in the previous scan.
Results:
The analysis revealed that linkage to chromosome 19q13 close to the APOE locus increased considerably as compared to the earlier scan. However, linkage to chromosome 10q21, which provided the strongest linkage in the previous scan could not be detected.
Conclusions:
The present investigation provides yet further evidence that 19q13 is the only chromosomal region consistently linked to Alzheimer&apos;s disease.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/122</link>
                <dc:creator>Elin Blom</dc:creator>
                <dc:creator>Vilmantas Giedraitis</dc:creator>
                <dc:creator>Sampath Arepalli</dc:creator>
                <dc:creator>Marian Hamshere</dc:creator>
                <dc:creator>Omanma Adighibe</dc:creator>
                <dc:creator>Alison Goate</dc:creator>
                <dc:creator>Julie Williams</dc:creator>
                <dc:creator>Lars Lannfelt</dc:creator>
                <dc:creator>John Hardy</dc:creator>
                <dc:creator>Fabienne Wavrant-De Vrieze</dc:creator>
                <dc:creator>Anna Glaser</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:122</dc:source>
        <dc:date>2009-12-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-122</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>122</prism:startingPage>
        <prism:publicationDate>2009-12-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/121">
        <title>Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis</title>
        <description>Background:
The genetic contribution to the aetiology of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is not well defined.  Across different autoimmune diseases some genes with immunomodulatory roles, such as PTPN22, are frequently associated with multiple diseases, whereas specific HLA associations, such as HLA-B27, tend to be disease restricted.  We studied ten candidate loci on the basis of their immunoregulatory role and prior associations with type 1 diabetes (T1D).  These included PTPN22, CTLA4 and CD226, which have previously been associated with AAV.
Methods:
We genotyped the following 11 SNPs, from 10 loci, in 641 AAV patients using TaqMan genotyping: rs2476601 in PTPN22, rs1990760 in IFIH1, rs3087243 in CTLA4, rs2069763 in IL2, rs10877012 in CYP27B1, rs2292239 in ERBB3, rs3184504 in SH2B3, rs12708716 in CLEC16A, rs1893217 and rs478582 in PTPN2 and rs763361 in CD226.  Where possible, we performed a meta-analysis with previous analyses.
Results:
Both CTLA4 rs3087243 and PTPN22 rs2476601 showed association with AAV, P = 6.4 x 10-3 and P = 1 x 10-4 respectively. The minor allele (A) of CTLA4 rs3087243 is protective (odds ratio = 0.84), whereas the minor allele (A) of PTPN22 rs2476601 confers susceptibility (odds ratio = 1.40).  These results confirmed previously described associations with AAV.  After meta-analysis, the rs2476601 association was further strengthened (combined P = 4.2 x 10-7, odds ratio of 1.48 for the A allele).  The other 9 SNPs, including rs763361 in CD226, showed no association with AAV.
Conclusions:
Our study of T1D associated SNPs in AAV has confirmed CTLA4 and PTPN22 as susceptibility loci in AAV.  These genes encode two key regulators of the immune response and are associated with many autoimmune diseases, including T1D, autoimmune thyroid disease, celiac disease, rheumatoid arthritis, and now AAV.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/121</link>
                <dc:creator>Edward Carr</dc:creator>
                <dc:creator>Heather Niederer</dc:creator>
                <dc:creator>Julie Williams</dc:creator>
                <dc:creator>Lorraine Harper</dc:creator>
                <dc:creator>Richard Watts</dc:creator>
                <dc:creator>Paul Lyons</dc:creator>
                <dc:creator>Kenneth Smith</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:121</dc:source>
        <dc:date>2009-12-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-121</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>121</prism:startingPage>
        <prism:publicationDate>2009-12-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/120">
        <title>Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia</title>
        <description>Background:
The aim of our study was to examine whether increased circulating total cell-free DNA levels are related to the clinical characteristics and standard laboratory parameters of preeclamptic patients, to markers of inflammation, endothelial activation or injury, oxidative stress and to cell-free fetal DNA levels.
Methods:
Circulating total cell-free DNA was measured by real-time quantitative PCR in plasma samples obtained from 67 preeclamptic and 70 normotensive pregnant women. Standard laboratory parameters, C-reactive protein, plasma von Willebrand factor antigen, plasma fibronectin, plasma malondialdehyde and cell-free fetal DNA levels were also determined.Results and ConclusionCirculating total cell-free and fetal deoxyribonucleic acid levels were significantly elevated in pregnancies complicated by preeclampsia (median: 11.395 vs. 32.460 and 0.001 vs. 0.086 pg/&#956;l; P &lt; .001). The quantity of plasma total cell-free DNA did not correlate with most of the laboratory parameters, except for serum aspartate aminotransferase and alanine aminotransferase activities (correlation coefficient: 0.31; P = 0.012 and 0.46; P &lt; .001). There was no correlation with clinical characteristics, including body mass index. The releases of both free fetal and total cell-free deoxyribonucleic acid were found to be affected in preeclampsia. Hepatocellular necrosis seems to be responsible - at least partly - for increased circulating total DNA levels in preeclampsia, as suggested by the significant correlation with liver enzyme activities.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/120</link>
                <dc:creator>Levente Lazar</dc:creator>
                <dc:creator>Janos Rigo</dc:creator>
                <dc:creator>Balint Nagy</dc:creator>
                <dc:creator>Krisztian Balogh</dc:creator>
                <dc:creator>Veronika Mako</dc:creator>
                <dc:creator>Laszlo Cervenak</dc:creator>
                <dc:creator>Miklos Mezes</dc:creator>
                <dc:creator>Zoltan Prohaszka</dc:creator>
                <dc:creator>Attila Molvarec</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:120</dc:source>
        <dc:date>2009-11-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-120</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>120</prism:startingPage>
        <prism:publicationDate>2009-11-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/119">
        <title>A novel study of Copy Number Variations in Hirschsprung disease using the Multiple Ligation-dependent Probe Amplification (MLPA) technique.</title>
        <description>Background:
Hirschsprung disease (HSCR) is a congenital malformation of the hindgut produced by a disruption in neural crest cell migration during embryonic development. HSCR has a complex genetic etiology and mutations in several genes, mainly the RET proto-oncogene, have been related to the disease. There is a clear predominance of missense/nonsense mutations in these genes whereas copy number variations (CNVs) have been seldom described, probably due to the limitations of conventional techniques usually employed for mutational analysis.
Methods:
In this study we have aimed to analyze the presence of CNVs in some HSCR genes (RET, EDN3, GDNF and ZFHX1B) using the Multiple Ligation-dependent Probe Amplification (MLPA) approach.
Results:
Two alterations in the MLPA profiles of RET and EDN3 were detected, but a detailed inspection showed that the decrease in the corresponding dosages were due to point mutations affecting the hybridization probes regions.
Conclusion:
Our results indicate that CNVs of the gene coding regions analyzed here are not a common molecular cause of Hirschsprung disease. However, further studies are required to determine the presence of CNVs affecting non-coding regulatory regions, as well as other candidate genes.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/119</link>
                <dc:creator>Rocio Nunez-Torres</dc:creator>
                <dc:creator>Raquel Fernandez</dc:creator>
                <dc:creator>Manuel Lopez-Alonso</dc:creator>
                <dc:creator>Guillermo Antinolo</dc:creator>
                <dc:creator>Salud Borrego</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:119</dc:source>
        <dc:date>2009-11-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-119</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>119</prism:startingPage>
        <prism:publicationDate>2009-11-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2350/10/118">
        <title>Emilin1 gene and essential hypertension: a two-stage association study in northern Han Chinese population</title>
        <description>Background:
Elastogenesis of elastic extracellular matrix (ECM) which was recognized as a major component of blood vessels has been believed for a long time to play only a passive role in the dynamic vascular changes of typical hypertension. Emilin1 gene participated in the transcription of ECM&apos;s formation and was recognized to modulate links TGF-&#946; maturation to blood pressure homeostasis in animal study. Recently relevant advances urge further researches to investigate the role of Emilin1 gene in regulating TGF-&#946; signals involved in elastogenesis and vascular cell defects of essential hypertension (EH).
Methods:
We designed a two-stage case-control study and selected three single nucleotide polymorphisms (SNPs), rs3754734, rs2011616 and rs2304682 from the HapMap database, which covered Emilin1 gene. Totally 2,586 subjects were recruited from the International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). In stage 1, all the three SNPs of the Emilin1 gene were genotyped and tested within a subsample including 503 cases and 490 controls, significant SNPs would enter into stage 2 including 814 cases with hypertension and 779 controls and analyze on the basis of testing total 2,586 subjects.
Results:
In stage 1, single locus analyses showed that SNPs rs3754734 and rs2011616 had significant association with EH (P &lt; 0.05). In stage 2, weak association for dominant model were observed by age stratification and odds ratio (ORs) of TG+GG vs. TT of rs3754734 were 0.768 (0.584-1.009), 0.985 (0.735-1.320) and 1.346 (1.003-1.806) in &lt; 50, 50-59 and &#8805; 60 years group and ORs of GA+AA vs. GG of rs2011616 were 0.745 (0.568-0.977), 1.013 (0.758-1.353) and 1.437 (1.072-1.926) in &lt; 50, 50-59 and &#8805; 60 years group respectively. Accordingly, significant interactions were detected between genotypes of rs3754734 and rs2011616 and age for EH, and ORs were 1.758 (1.180-2.620), P = 0.006 and 1.903 (1.281-2.825), P = 0.001, respectively. Results of haplotypes analysis showed that there weren&apos;t any haplotypes associated with EH directly, but the interaction of hap2 (GA) and age-group found to be significant after being adjusted for the covariates, OR was 1.220 (1.031-1.444), P value was 0.020.
Conclusion:
Our findings don&apos;t support positive association of Emilin1 gene with EH, but the interaction of age and genotype variation of rs3754734 and rs2011616 might increase the risk to hypertension.</description>
        <link>http://www.biomedcentral.com/1471-2350/10/118</link>
                <dc:creator>Chong Shen</dc:creator>
                <dc:creator>Xiangfeng Lu</dc:creator>
                <dc:creator>Yun Li</dc:creator>
                <dc:creator>Qi Zhao</dc:creator>
                <dc:creator>Xiaoli Liu</dc:creator>
                <dc:creator>Liping Hou</dc:creator>
                <dc:creator>Laiyuan Wang</dc:creator>
                <dc:creator>Shufeng Chen</dc:creator>
                <dc:creator>Jianfeng Huang</dc:creator>
                <dc:creator>Dongfeng Gu</dc:creator>
                <dc:source>BMC Medical Genetics 2009, 10:118</dc:source>
        <dc:date>2009-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2350-10-118</dc:identifier>
        <prism:publicationName>BMC Medical Genetics</prism:publicationName>
        <prism:issn>1471-2350</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>118</prism:startingPage>
        <prism:publicationDate>2009-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
